BioMarin Pharmaceutical

Immix Biopharma 12 Month Review Progress Update

Retrieved on: 
Wednesday, February 21, 2024

LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.

Key Points: 
  • LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.
  • “The past 12 months have seen landmark achievements for Immix Biopharma, cementing our position as a leading cell therapy company in autoimmune disease.
  • NXC-201 is the first and only ‘Single-Day CRS‘ CAR-T, a critical advancement for autoimmune diseases like AL Amyloidosis,” said Ilya Rachman, MD PhD CEO Immix Biopharma.
  • As we reflect on the last 12 months of progress, we wish to connect with you offering an update on Immix Biopharma.

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Wednesday, February 28, 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2023.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2023.
  • Beginning in the fourth quarter of 2023, amortization of in-licensed rights (formerly included within depreciation and amortization expense) and income tax (benefit) expense are no longer excluded from the non-GAAP results.
  • Non-GAAP financial results for the fourth quarter and full-year 2022 have been updated to reflect this change for comparability.
  • All relevant non-GAAP measures are reconciled from their respective GAAP measures in the attached table “Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures.”

NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

Retrieved on: 
Tuesday, February 27, 2024

NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024.

Key Points: 
  • NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024.
  • "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar.
  • She is currently a Board Director for Enovis Corporation (NYSE: ENOV), Option Care Health (NASDAQ: OPCH) and BioMarin Pharmaceutical (NASDAQ: BMRN).
  • “2024 and the next few years will be critical for NorthStar,” said Frank Scholz, Ph.D., NorthStar President and Chief Executive Officer.

BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

Retrieved on: 
Thursday, March 7, 2024

SAN RAFAEL, Calif., March 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer. Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer.

Key Points: 
  • SAN RAFAEL, Calif., March 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer.
  • Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer.
  • Ms. Hubbard is a proven leader who brings to BioMarin more than 20 years of experience in the biopharmaceutical and diagnostics industries.
  • He has worked at BioMarin for more than 18 years, including 11 as chief commercial officer.

BioMarin Scheduled to Participate in March Investor Conferences

Retrieved on: 
Friday, March 1, 2024

SAN RAFAEL, Calif., March 1, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management is scheduled to participate in four upcoming investor conferences in March.

Key Points: 
  • SAN RAFAEL, Calif., March 1, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management is scheduled to participate in four upcoming investor conferences in March.
  • Cowen 44th Annual Healthcare Conference (Boston, MA)
    Leerink Partners Global BioPharma Conference (Miami, FL)
    Jefferies Biotech on the Bay Summit (Miami, FL)
    Barclays 26th Annual Global Healthcare Conference (Miami, FL)
    The live webcast of the fireside chat can be accessed by visiting BioMarin's website at https://investors.biomarin.com/ .
  • A webcast replay will be available through the Company's website for a limited time following the conferences.

BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET

Retrieved on: 
Thursday, February 8, 2024

SAN RAFAEL, Calif., Feb. 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 22, at 4:30 p.m.

Key Points: 
  • SAN RAFAEL, Calif., Feb. 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 22, at 4:30 p.m.
  • ET to discuss fourth quarter and full-year 2023 financial results and provide a general business update.
  • U.S. / Canada Replay Dial-in Number: 800-770-2030
    Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/ .
  • A replay of the call will be archived on the site for one week following the call.

BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress

Retrieved on: 
Tuesday, February 6, 2024

SAN RAFAEL, Calif., Feb. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that new data on ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) will be presented at the 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress, Feb. 6-9, 2024.

Key Points: 
  • SAN RAFAEL, Calif., Feb. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that new data on ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) will be presented at the 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress, Feb. 6-9, 2024.
  • The majority of participants maintained hemostasis, with only two of the seven participants in the study returning to regular prophylaxis, and no new safety signals emerged.
  • These data will be presented as a poster presentation from 6:30-7:30 p.m. Central European Time (CET) on Wednesday, Feb. 7.
  • "We are pleased to present data showing the impact of one-time treatment with ROCTAVIAN over seven years following the infusion, underscoring the potential of gene therapy to make a meaningful and long-lasting impact for people living with severe hemophilia A."

TORL BioTherapeutics Announces Appointment of Mark J. Alles as Chairman and Chief Executive Officer; Highlights Significant Progress of its Oncology Clinical Programs

Retrieved on: 
Tuesday, January 9, 2024

Mark Alles, Executive Chairman of TORL BioTherapeutics, LLC (TORL) and former Chairman and CEO of Celgene Corporation has been appointed TORL's Chairman and CEO.

Key Points: 
  • Mark Alles, Executive Chairman of TORL BioTherapeutics, LLC (TORL) and former Chairman and CEO of Celgene Corporation has been appointed TORL's Chairman and CEO.
  • Today, the company announced the appointment of Mark J.  Alles, TORL's Executive Chairman, as the company's new Chairman and CEO.
  • Prior to joining Celgene in 2004, Mr. Alles was Vice President of the U.S. Oncology business unit at Aventis Pharmaceuticals.
  • He began his industry career at Bayer and Centocor after serving as a Captain in the United States Marine Corps.

Be Biopharma Expands Leadership Team as Company Transitions to Clinical Stage Organization

Retrieved on: 
Thursday, January 4, 2024

Mr. Smith also brings nearly a decade of investment banking experience, providing strategic and financial advice across the healthcare sector.

Key Points: 
  • Mr. Smith also brings nearly a decade of investment banking experience, providing strategic and financial advice across the healthcare sector.
  • “We are thrilled to welcome Angus and Wing to Be Bio,” said Joanne Smith-Farrell, Ph.D., Chief Executive Officer.
  • These accomplished and experienced leaders will further strengthen our leadership team.
  • During his nearly decade-long investment banking tenure, Mr. Smith provided strategic and financial advice to life sciences and healthcare companies.

Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer

Retrieved on: 
Thursday, January 4, 2024

CELEBRATION, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer.

Key Points: 
  • CELEBRATION, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer.
  • Dr. Quartel brings more than 20 years of experience in the international pharmaceutical industry with senior roles in clinical development, pharmacovigilance and medical affairs.
  • "It is an honor to welcome Dr. Quartel to our team during an exciting period of growth for Zevra after our recent acquisition of Acer Therapeutics and the expansion of our rare disease portfolio,” said Neil F. McFarlane, President and Chief Executive Officer of Zevra.
  • Prior to that, he was the Chief Medical Officer at Adamas Pharmaceuticals, a company focused on drug development for neurological diseases.